TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32810220
Drug: Ofatumumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (1000 mg)
Study: 36431201
Drug: Standardized punicalagin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized punicalagin enriched oral pomegranate extract (Pomella®) daily for four weeks
Study: 34053748
Drug: Oral regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral regimen causing moderate nausea
Study: 34053748
Drug: Monthly IV
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly IV regimen causing mild memory problems
Study: 34053748
Drug: Weekly IV
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly IV regimen causing mild memory and mild neuropathy
Study: 32967068
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D (ergocalciferol) at 40,000 IU per week
Study: 32405570
Drug: High NO3−
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NO3− (140 ml of beetroot juice (BJ) per day, 800 mg of NO3−/day)
Study: 32405570
Drug: Moderate NO3−
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate NO3− (70 ml of BJ per day, 400 mg of NO3−/day)
Study: 32405570
Drug: Low NO3−
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NO3− (70 ml on alternate days, 400 mg of NO3−)
Study: 32405570
Drug: NO3− depleted
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3− depleted (70 ml on alternate days, 0.001 mg of NO3)
Study: 33639543
Drug: Heart-focused breathing
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart-focused breathing protocol (10 minutes daily for 2 weeks)
Study: 32375661
Drug: Digital reminiscence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital reminiscence therapy (digital RT), 8 sessions over 4 weeks.
Study: 32375661
Drug: Conventional reminiscence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional reminiscence therapy (storytelling, control group), 8 sessions over 4 weeks.
Study: 32815384
Drug: Standard physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiotherapy treatment
Study: 34183510
Drug: Non-antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotic treatment (anti-inflammatory and symptomatic treatment)
Study: 34183510
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (875/125 mg/8 h amoxicillin/clavulanic acid)
Study: 34102933
Drug: Daily screen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily screen time
Study: 33316557
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic treatment
Study: 32736597
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg twice daily on day 1, followed by 200 mg twice daily on days 8, 15, and 22 for Group 1; 400 mg twice daily on day 1 followed by 200 mg twice daily for 5-7 days for Group 2)
Study: 38174567
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy (DAPT)
Study: 35960075
Drug: astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: astragalus injection with chemotherapy regimen containing anthracycline epirubicin
Study: 35960075
Drug: chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy regimen containing anthracycline epirubicin
Study: 39206189
Drug: AS03-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted vaccine
Study: 35149205
Drug: AYUSH‐64 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: AYUSH‐64 (two tablets of 500 mg each, three times a day for 30 days)
Study: 36164014
Drug: Momelotinib (MMB)
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib (MMB) 200 mg QD for 24 weeks
Study: 36164014
Drug: Danazol (DAN)
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol (DAN) 600 mg QD for 24 weeks
Study: 33611104
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg daily (n = 261)
Study: 35246053
Drug: Usual care-control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care-control group (routine care for the prevention or treatment of diseases).
Study: 33459247
Drug: Methyl Jasmonate
Normalized name: jasmone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl Jasmonate (MJ) treatment at 30 mM
Study: 33459247
Drug: Methyl Jasmonate
Normalized name: jasmone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl Jasmonate (MJ) treatment at 60 mM
Study: 33459247
Drug: Methyl Jasmonate
Normalized name: jasmone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl Jasmonate (MJ) treatment at 100 mM
Study: 34606114
Drug: Two-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose group (tetravalent measles-mumps-rubella-varicella vaccine)
Study: 34606114
Drug: One-dose group
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose group (monovalent varicella vaccine)
Study: 33872815
Drug: Follicular flushing
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follicular flushing (FF) using a 17-G double lumen needle
Study: 33872815
Drug: Direct follicular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct follicular aspiration using a 17-G single lumen needle
Study: 36346534
Drug: Safinamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide (50 mg once daily, increased to 100 mg once daily at day 15)
Study: 32003644
Drug: Trigonal Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonal Botulinum toxin‐A (BTX‐A) injections (240 U into the detrusor plus 60 U into the trigone)
Study: 32003644
Drug: Nontrigonal Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontrigonal Botulinum toxin‐A (BTX‐A) injections (300 U into the detrusor sparing the trigone)
Study: 32293523
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) 150 mg/day for 60 days
Study: 32293523
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) 400 mg/day for 15 days
Study: 32293523
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) 300 mg/day for 60 days (comparator arm)
Study: 35084435
Drug: BQ-123 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (selective ETA receptor antagonist)
Study: 33252549
Drug: 30 tablets
Normalized name: nitrogen 30 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 tablets of hydrocodone/acetaminophen 10 to 325 mg
Study: 33252549
Drug: 60 tablets
Normalized name: Polysorbate 60
DrugBank: Polysorbate 60 (DB14153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 tablets of hydrocodone/acetaminophen 10 to 325 mg
Study: 33177393
Drug: 0.005% calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% calcipotriol ointment
Study: 33843675
Drug: Blue-green (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue-green (500 nm) light therapy for SCD treatment
Study: 33843675
Drug: Blue-green (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue-green (500 nm) light therapy for aMCI treatment
Study: 34129743
Drug: Standardised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised exercise programme for the jaw and orofacial muscles and individualised oral hygiene programme
Study: 89344702
Drug: Three reduced
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three reduced doses of Merck Sharp and Dohme (MSD) H‐B Vax plasma derived vaccine (2 micrograms each) given intramuscularly at monthly intervals.
Study: 33573696
Drug: Nilavembu Kudineer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilavembu Kudineer (60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Study: 33573696
Drug: Kaba Sura
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaba Sura Kudineer (60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Study: 33573696
Drug: Decaffeinated Tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated Tea (Placebo - 60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Study: 32424455
Drug: Pelvic Organ
Normalized name: ProVate Pelvic Organ Prolapse Supports (61mm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic Organ Prolapse Suspension (POPS)
Study: 34714139
Drug: RI aqueous
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RI aqueous extract fluid of 1.78 mg/mL
Study: 34714139
Drug: RI aqueous
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RI aqueous extract fluid of 2.66 mg/mL
Study: 39028879
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOAC)
Study: 33852339
Drug: PARP inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitors (PARPi) - olaparib and talazoparib, provided in capsule form
Study: 33147665
Drug: Ingenol disoxate
Normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingenol disoxate gel (IngDsx, 0.018% for face/chest; 0.037% for scalp)
Study: 34162825
Drug: General awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: General awareness of oral cancer
Study: 34162825
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of risk factors for oral cancer
Study: 32525235
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy Continuation (MBCT-C) for 26 weeks
Study: 32108029
Drug: Low-Carbohydrate Diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Carbohydrate Diet (LCD) - instructed to eat <20 g/carbs/day
Study: 32293810
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Group C)
Study: 34179755
Drug: Lidocaine trigger
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine trigger point injection
Study: 34179755
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline interfascial injection
Study: 616117791
Drug: Liposomal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal spray containing phosphatidylcholine (PC) (Tears again, BioRevive)
Study: 616117791
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline spray
Study: 32216042
Drug: Chemotherapy-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-only group
Study: 33223272
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (specifics not provided)
Study: 35351535
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg/day for 24 weeks
Study: 37314275
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment
Study: 32432326
Drug: Intrauterine insemination
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine insemination (IUI) with timing from hCG injection
Study: 35372576
Drug: Peripheral Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral Intravenous Thrombolysis (PIT)
Study: 34528282
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg PMO once daily
Study: 34528282
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg PMO twice daily
Study: 34528282
Drug: 540 mg
Normalized name: lecithin 540 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 540 mg PMO thrice daily
Study: 33964572
Drug: ALP 250
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALP 250 mg + EVE 2.5 mg
Study: 33964572
Drug: ALP 200
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALP 200 mg + EVE 2.5 mg + EXE 25 mg
Study: 33832878
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) plus Best Supportive Care (BSC)
Study: 33832878
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg) plus erlotinib (25 mg/day)
Study: 32638373
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine treatment
Study: 32638373
Drug: Cytarabine as
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine as a single agent
Study: 32629668
Drug: Low-dose glucocorticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoids + methotrexate + hydroxychloroquine
Study: 35725261
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nurse-led volunteer support and technology-driven pain assessment
Study: 33983564
Drug: 8% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% capsaicin cutaneous patch
Study: 33826656
Drug: Metformin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (doses ranging from 500-1500mg)
Study: 33826656
Drug: Physiologically based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologically based pharmacokinetic (PBPK) model for metformin in humans
Study: 33826656
Drug: PBPK model
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBPK model for metformin in mice
Study: 33115543
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg orally daily for 14 days)
Study: 36189751
Drug: IV push
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV push administration of levetiracetam
Study: 36189751
Drug: IV piggyback
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV piggyback administration of levetiracetam
Study: 38421679
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injection
Study: 36884302
Drug: Dabrafenib monotherapy
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib monotherapy
Study: 34902262
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus a single subcutaneous dose of sarilumab 400 mg
Study: 34902262
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus a single subcutaneous dose of sarilumab 200 mg
Study: 33380581
Drug: Hydrogen-rich gas
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich gas (HG) inhalation during a 60-minute recovery phase after exercise
Study: 33380581
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (ambient air) during a 60-minute recovery phase after exercise
Study: 34928519
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml thin liquid bolus
Study: 34928519
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml thin liquid bolus
Study: 34928519
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml thin liquid bolus
Study: 34928519
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml thick liquid bolus
Study: 32312337
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (containing at least 250 mg DHA and at least 60 mg EPA)
Study: 35043869
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral erector spinae plane block combined with intravenous patient-controlled analgesia (iv PCA)
Study: 35043869
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (iv PCA) alone
Study: 34229862
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% plus dexmedetomidine 1 μg.kg‐1
Study: 34913825
Drug: Econazole 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole 250 mg
Study: 34913825
Drug: Econazole 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole 500 mg
Study: 34913825
Drug: Econazole 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole 1000 mg
Study: 33644986
Drug: Soft-tissue mobilization
Normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soft-tissue mobilization therapy and 20 spinal mobility exercises
Study: 32338931
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive therapy (EBCT)
Study: 32811734
Drug: Trimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodal therapy consisting of 2% Nitroglycerine (NTG), Hyperbaric Oxygen Therapy (HBOT), and local steroids
Study: 32811734
Drug: Nitroglycerine (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (NTG) and local steroids (without HBOT)
Study: 36309759
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg oral bosentan, twice a day for 8 weeks
Study: 33627329
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (standard management)
Study: 33627329
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose) infusion (restrictive management)
Study: 34044534
Drug: Cyclic peptide
Normalized name: Cyclic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic peptide inhibitors of FXIIa
Study: 33124895
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Levilactobacillus brevis CECT7480 and Lactoplantibacillus plantarum CECT7481), 2 tablets per day for 1 week
Study: 34639746
Drug: CPSCoD training
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPSCoD training (twice weekly for 8 weeks)
Study: 36045965
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray combined with loratadine
Study: 36096534
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg) every 4 weeks until worsening or unacceptable toxicity
Study: 36183101
Drug: Aqueous crystalline
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous crystalline penicillin G (ACPG)
Study: 39424558
Drug: Alteplase 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 0.9 mg/kg
Study: 39424558
Drug: Tenecteplase 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.25 mg/kg
Study: 33721689
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (active)
Study: 33721689
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (passive)
Study: 36841762
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg/day
Study: 39160110
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen therapy (HFNO)
Study: 39111953
Drug: Sacubitril/Valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan 200 mg twice daily
Study: 36082663
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg twice daily
Study: 32331024
Drug: AMPH EROS
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH EROS 20 mg fasted
Study: 35555189
Drug: Creatine Nitrate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine Nitrate (CN: 5 g/day + 0.675 g/day of maltodextrin)
Study: 33927343
Drug: Selective progesterone
Normalized name: Selective progesterone receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective progesterone receptor modulator (SPRM)
Study: 39539664
Drug: Anticoagulant monotherapy
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant monotherapy
Study: 32307878
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Sustanon® (testosterone ester injections)
Study: 32653333
Drug: Intravenous cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cetirizine 10 mg
Study: 32653333
Drug: Intravenous diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diphenhydramine 50 mg
Study: 35482774
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to aerobic exercise prescription (at least two-thirds of the prescribed exercise)
Study: 38598227
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy
Study: 33666264
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PC) in addition to traditional care
Study: 35044972
Drug: Topical amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amphotericin B 0.15% plus CXL
Study: 34818273
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin Type A (BTX) intradermal injections to the treated side of the inframammary incision
Study: 35017306
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for acute ischemic stroke (AIS) in patients with active cancer